Literature DB >> 10413703

Effect of the cytostatic agent idarubicin on fibroblasts of the human Tenon's capsule compared with mitomycin C.

C Heilmann1, P Schönfeld, T Schlüter, R Bohnensack, W Behrens-Baumann.   

Abstract

BACKGROUND/AIMS: To investigate the in vitro effect of a short time exposure to the anthracycline idarubicin on proliferation, protein synthesis, and motility of human Tenon's capsule fibroblasts in comparison with the antitumour antibiotic mitomycin C.
METHODS: After determination of effective concentrations of idarubicin, fibroblasts of the human Tenon's capsule were exposed to idarubicin or mitomycin C at concentrations ranging from 0.1 microg/ml to 1 microg/ml or from 2.5 microg/ml to 250 microg/ml, respectively, for 0.5, 2, or 5 minutes and cultured for 60 days. Cell death by apoptosis caused by idarubicin treatment was confirmed by Hoechst 33258 staining. Further proliferation was explored by cell counting and by (3)H-thymidine uptake. Protein synthesis was measured by (3)H-proline uptake and motility was assessed by agarose droplet motility assay.
RESULTS: Idarubicin is able to exert toxicity and to induce apoptosis during a short time exposure of 0.5 minutes at concentrations of 0.3-1 microg/ml resulting in a significant reduction in cell number compared with the control after 60 days. For mitomycin C, higher concentrations and longer expositions were necessary. Even after treatment with 1 microg/ml idarubicin or 250 microg/ml mitomycin C a few cells were able to incorporate (3)H-thymidine. (3)H-proline uptake up to 10 days after exposure to 0.3 microg/ml idarubicin was found not to be decreased. Cell motility was reduced after treatment with 1 microg/ml idarubicin for 5 minutes or with 250 microg/ml mitomycin C for 2 or 5 minutes. For low mitomycin C concentrations, an increase in motility was found during the first 10 days.
CONCLUSION: Idarubicin reduces proliferation of human Tenons's capsule fibroblasts after incubation for 0.5 minutes at concentrations as low as 0.3-1 microg/ml. In comparison, mitomycin C requires longer exposure times and higher doses for equal results. Therefore, idarubicin may be useful in the prevention of glaucoma filtering surgery failure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10413703      PMCID: PMC1723157          DOI: 10.1136/bjo.83.8.961

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  21 in total

1.  Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts.

Authors:  P T Khaw; M B Sherwood; S L MacKay; M J Rossi; G Schultz
Journal:  Arch Ophthalmol       Date:  1992-08

2.  Hypotony maculopathy following trabeculectomy with mitomycin C.

Authors:  H D Jampel; L R Pasquale; C Dibernardo
Journal:  Arch Ophthalmol       Date:  1992-08

3.  Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.

Authors:  E Berman; M McBride
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

4.  The effects of D-penicillamine and daunorubicin on conjunctival fibroblast proliferation and collagen synthesis.

Authors:  L J McGuigan; H A Quigley; G Lutty; C Enger; E Young
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-01       Impact factor: 4.799

5.  Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding.

Authors:  F Gieseler; H Biersack; T Brieden; J Manderscheid; V Nüssler
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

6.  Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines.

Authors:  R Testi; L Mattii; D Di Simone; L Zaccaro; G Malvaldi; B Grassi; M Petrini
Journal:  Leuk Res       Date:  1995-04       Impact factor: 3.156

7.  Trabeculectomy with mitomycin. A comparative study with fluorouracil.

Authors:  Y Kitazawa; K Kawase; H Matsushita; M Minobe
Journal:  Arch Ophthalmol       Date:  1991-12

8.  DNA fragmentation as a consequence of cell cycle traverse in doxorubicin- and idarubicin-treated human lymphoma cells.

Authors:  P J Smith; C Rackstraw; F Cotter
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

9.  Long-term effects of mitomycin on filtering blebs. Lack of fibrovascular proliferative response following severe inflammation.

Authors:  M K Yaldo; R L Stamper
Journal:  Arch Ophthalmol       Date:  1993-06

10.  In vitro sensitivity of human Tenon's capsule fibroblasts to mitomycin C and its correlation with outcome of glaucoma filtration surgery.

Authors:  H N Madhavan; S B Rao; L Vijaya; A Neelakantan
Journal:  Ophthalmic Surg       Date:  1995 Jan-Feb
View more
  1 in total

1.  AQ4, an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: implications for the therapy of ocular neovascular disorders.

Authors:  Swita Raghava; Uday B Kompella
Journal:  Eur J Pharmacol       Date:  2007-05-06       Impact factor: 4.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.